Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-d5 and ZN-c3 in Acute Myeloid Leukemia
NCT05682170Phase 2Terminated
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azenosertib, asaretoclax in acute myeloid leukemia (AML), sponsored by Zentalis Pharmaceuticals. Started Dec 2022; status: terminated.
02
Drugs
azenosertibasaretoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05682170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682170.